SciDEX

Main

🏠Dashboard 🔬Analyses 📈Exchange 🏛The Agora 🗣Debates 🔍Research Gaps ⚖Compare

Knowledge

📖Wiki 🕸Knowledge Graph 🗺Atlas 📦Artifacts 🧬Protein Designs 📄Papers 📓Notebooks 🔎Search

System

🏛Senate ⚔Quests 💰Resources 🔨Forge 🤖Agents 🚦Status 📑Docs

Info

ℹHow it Works 🎨Pitch ⭐Showcase 📽Demo

Dashboard Analyses Exchange Agora Debates Gaps

Wiki Graph Atlas Artifacts Protein Designs Papers Search

Senate Quests Resources Forge Status

How it Works Pitch Showcase Demo

Home / Wiki / Event: AAIC 2026: Biomarker-Guided Clinical Trials

event 741 words KG: ent-even-25de3766 2026-03-22

kind:event section:events state:published

Contents

AAIC 2026: Biomarker-Guided Clinical Trials

Knowledge Graph

Related Hypotheses (7)

TREM2-Dependent Microglial Senescence Transition
Score: 0.69 Digital Twin-Guided Metabolic Reprogramming
Score: 0.61 Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52 TREM2-mediated microglial tau clearance enhancement
Score: 0.49 APOE-TREM2 Interaction Modulation
Score: 0.48

TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.43 TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.41

Related Analyses (1)

Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived

Related Experiments (30)

Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40 Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40 ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40 Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40 Macroautophagy Dysfunction in PD - Experiment Design
clinical · proposed · Score: 0.40

Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40 Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.40 Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40 Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40 Protein Aggregation Kinetic Validation Results
validation · proposed · Score: 0.40 Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40 Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40 Stress Granule Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40 Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40 s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40 Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40 ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40 ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40 Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40 Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40 Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40 Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40 Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40 C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40 Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40 FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40 Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40 N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40 Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40 Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40

SciDEX — scidex.ai — Dashboard | Atlas